Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis.

@article{Iacovelli2015InhibitionOT,
  title={Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis.},
  author={Roberto Iacovelli and Cora N Sternberg and Camillo Porta and Elena Verzoni and Filippo Guglielmo de Braud and Bernard Escudier and Giuseppe Procopio},
  journal={Current drug targets},
  year={2015},
  volume={16 2},
  pages={
          164-70
        }
}
Despite the improvement in progression-free survival and response rates, none of the five anti- VEGF/VEGFR agents used for treatment of metastatic renal cell carcinoma (mRCC) reported a significant increase in patients' survival. This analysis aims to investigate their effect on overall survival (OS), performing a meta-analysis of the available studies. MEDLINE/PubMed and the Cochrane Library were searched for randomised phase III trials that compared anti-VEGF/VEGFR agents with controls as… CONTINUE READING